Cannabis

Drug Abuse and Addiction in Medical Illness: Causes, Consequences and Treatment

Volumn 9781461433750, Issue , 2012, Pages 151-162

  Jager, Gerry ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892483056     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3375-0_11     Document Type: Chapter

References (89)

1. Iversen LL. The science of marijuana. Oxford, UK: Oxford University Press; 2000.
2. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47 Suppl 1:345-58.
3. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006;46:101-22.
4. UNODC. World Drug Report 2008. Vienna: United Nations Office on Drugs and Crime; 2008.
5. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14(9):923-30.
6. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007;9(4):413-30.
7. Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth. 2008;101(1):59-68.
8. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol. 2008; 13(2):147-59.
9. NDM. NDM annual report 2006. Utrecht: Trimbos Instituut; 2007.
10. SAMHSA. The national survey on drug use and health. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA); 2005.
11. NIDA. Research report series marijuana abuse. Lexington, KY: National Institute on Drug Abuse; 2005.
12. Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94(9):1311-22.
13. Budney AJ, Hughes JR, Moore BA, Novy PL. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry. 2001;58(10):917-24.
14. EMCDDA. Annual report 2007. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2007.
15. EMCDDA. Annual report 2004. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2004.
16. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, et al. Cannabis withdrawal among non-treatmentseeking adult cannabis users. Am J Addict. 2006;15(1):8-14.
17. Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000;108(1-2):1-13.
18. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classi fication of cannabinoid receptors. Pharmacol Rev. 2002;54(2): 161-202.
19. Hollister LE. Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9- tetrahydrocannabinol. Pharmacology. 1974;11(1):3-11.
20. Jones G, Pertwee RG, Gill EW, Paton WD, Nilsson IM, Widman M, et al. Relative pharmacological potency in mice of optical isomers of delta 1-tetrahydrocannabinol. Biochem Pharmacol. 1974;23(2):439-46.
21. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11(2):563-83.
22. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-4.
23. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005;106(2):133-45.
24. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3): 389-462.
25. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4(11):873-84.
26. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017-66.
27. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sci. 2005;77(14):1667-73.
28. de Rodriguez FF, Del A, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005;40(1):2-14.
29. Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 2003;169(2):135-40.
30. Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav. 2005;81(2):285-99.
31. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology (Berl). 2003;169(2):115-34.
32. Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinolinduced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol. 2004;506(1):63-9.
33. Valjent E, Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology (Berl). 2000;147(4):436-8.
34. Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA. Two brain sites for cannabinoid reward. J Neurosci. 2006;26(18): 4901-7.
35. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, et al. Delta9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology. 2009;34(3):759-66.
36. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther. 2002;95(2):153-64.
37. Nava F, Carta G, Colombo G, Gessa GL. Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. Neuropharmacology. 2001;41(3):392-9.
38. Kirk JM, de WH. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav. 1999;63(1):137-42.
39. Swift W, Hall W, Teesson M. Characteristics of DSM-IV and ICD- 10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Drug Alcohol Depend. 2001;63(2):147-53.
40. Meyer JS, Quenzer LF. Marijuana and the cannabinoids. In: Psychopharmacology, Drugs, the brain, and behavior. Massachusetts, USA: Sinauer Associates; 2005. p. 327-46.
41. Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, Tanda G, et al. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology. 2008;33(12):2870-7.
42. Aceto MD, Scates SM, Lowe JA, Martin BR. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther. 1996;278(3):1290-5.
43. Wilson DM, Varvel SA, Harloe JP, Martin BR, Lichtman AH. SR 141716 (Rimonabant) precipitates withdrawal in marijuanadependent mice. Pharmacol Biochem Behav. 2006;85(1):105-13.
44. Paton WDM, Pertwee RG. The actions of cannabis in man. In: Mechoulam R, editor. Marijuana. New York: Academic; 1973. p. 287-333.
45. Solowij N. Cannabis and cognitive functioning. Cambridge: Cambridge University Press; 1998.
46. Heishman SJ. Effects of marijuana on human performance and assessment of driving impairment. In: Onaivi ES, editor. Biology of marijuana: from gene to behavior. New York: Taylor and Francis; 2002. p. 308-32.
47. Castle D, Murray R, editors. Marijuana and madness: psychiatry and neurobiology. Cambridge: Cambridge University Press; 2004.
48. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-60.
49. Pope HG, Yurgelun-Todd D. Residual cognitive effects of longterm cannabis use. In: Castle D, Murray R, editors. Marijuana and madness: psychiatry and neurobiology. Cambridge: Cambridge University Press; 2004. p. 198-210.
50. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev. 2007;17(3):347-61.
51. Green B, Kavanagh D, Young R. Being stoned: a review of selfreported cannabis effects. Drug Alcohol Rev. 2003;22(4):453-60.
52. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de WH. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl). 2002;161(4):331-9.
53. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999;58(4):315-48.
54. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 1996;42(3):201-7.
55. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006;188(4):425-44.
56. McDonald J, Schleifer L, Richards JB, de WH. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology. 2003;28(7):1356-65.
57. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ. Acute marijuana effects on human risk taking. Neuropsychopharmacology. 2005;30(4):800-9.
58. Ramaekers JG, Kauert G, van RP, Theunissen EL, Schneider E, Moeller MR. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31(10):2296-303.
59. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral Delta 9- tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl). 2002;164(1):61-70.
60. Hart CL, van GW, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001;25(5):757-65.
61. Quickfall J, Crockford D. Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci. 2006;18(3):318-32.
62. Chang L, Chronicle EP. Functional imaging studies in cannabis users. Neuroscientist. 2007;13(5):422-32.
63. O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology. 2002;26(6): 802-16.
64. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de WH. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci. 2008;28(10): 2313-9.
65. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, et al. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry. 2008;64(11):966-73.
66. Jager G, Ramsey NF. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: an overview of animal and human research. Curr Drug Abuse Rev. 2008;1:114-23.
67. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370(9584):319-28.
68. Di FM, Morrison PD, Butt A, Murray RM. Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Curr Opin Psychiatry. 2007;20(3):228-34.
69. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol. 2008;13(2):264-75.
70. Pope Jr HG. Cannabis, cognition, and residual confounding. JAMA. 2002;287(9):1172-4.
71. Pope Jr HG, Gruber AJ, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995;38(1):25-34.
72. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287(9):1123-31.
73. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2008;1:81-98.
74. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9(5):679-89.
75. Nair DG. About being BOLD. Brain Res Brain Res Rev. 2005;50(2):229-43.
76. Jager G, Van Hell HH, De Win MM, Kahn RS, Van Den Brink W, Van Ree JM, et al. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol. 2007;17(4):289-97.
77. Sneider JT, Pope Jr HG, Silveri MM, Simpson NS, Gruber SA, Yurgelun-Todd DA. Altered regional blood volume in chronic cannabis smokers. Exp Clin Psychopharmacol. 2006;14(4):422-8.
78. Murray RM, Morrison PD, Henquet C, Di FM. Cannabis, the mind and society: the harsh realities. Nat Rev Neurosci. 2007;8(11): 885-95.
79. Sundram S. Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol. 2006;21(4):245-54.
80. Grech A, van OJ, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005;20(4):349-53.
81. Boydell J, van OJ, Caspi A, Kennedy N, Giouroukou E, Fearon P, et al. Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med. 2006;36(10):1441-6.
82. Rathbone J, Variend H, Mehta H. Cannabis and schizophrenia. Cochrane Database Syst Rev 2008;(3):CD004837.
83. Sarne Y, Keren O. Are cannabinoid drugs neurotoxic or neuroprotective? Med Hypotheses. 2004;63(2):187-92.
84. Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord. 2005;4(6):677-84.
85. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 2003;11(3):137-43.
86. Fogarty A, Rawstorne P, Prestage G, Crawford J, Grierson J, Kippax S. Marijuana as therapy for people living with HIV/AIDS: social and health aspects. AIDS Care. 2007;19(2):295-301.
87. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005;7(3):E625-54.
88. Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2009;23(5):597-602.
89. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry. 2007;62(10):1103-10.